Canaccord Genuity Initiates Actinium Pharmaceuticals At Buy

Analysts at Canaccord Genuity initiated coverage on shares of Actinium Pharmaceuticals

with a Buy rating. The target price for Actinium Pharmaceuticals is set to $16. Actinium Pharmaceuticals shares have surged 104.12% over the past 52 weeks, while the S&P 500 index has jumped 16.40% in the same period. Actinium Pharmaceuticals' shares declined 4.28% to close at $6.94 yesterday.